Fusion protein with stable regulatory T cell differentiation, recombinant lentivirus and application
The invention provides a fusion protein with stable regulatory T cell differentiation, a recombinant lentivirus and application. The fusion protein comprises three structural domains, the first structural domain is a chemotactic factor ligand, the second structural domain is an intermediate bridging structural domain, and the third structural domain is a bZIP factor of human T-cell viro-1; the chemotactic factor ligand is CCL17 or CCL22, and the intermediate bridging structural domain is a flexible (GGGGS) 3 sequence; the bZIP factor of the human T cell viro-1 is HBZ (Hepatitis B Z). The fusion protein and the recombinant lentivirus both have the capabilities of promoting the differentiation of initial T cells to Treg cells and promoting the proliferation of the Treg cells, and have application potentials in the aspects of in-vitro Treg cell culture and amplification and the application of treating autoimmune diseases..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 14. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHU XIAOFEI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-14, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
CN117050192 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019119070 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019119070 | ||
| 003 | DE-627 | ||
| 005 | 20240209083353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019119070 | ||
| 035 | |a (EPA)CN117050192 | ||
| 035 | |a (EPA)88661521 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHU XIAOFEI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fusion protein with stable regulatory T cell differentiation, recombinant lentivirus and application |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-14, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 | ||
| 520 | |a The invention provides a fusion protein with stable regulatory T cell differentiation, a recombinant lentivirus and application. The fusion protein comprises three structural domains, the first structural domain is a chemotactic factor ligand, the second structural domain is an intermediate bridging structural domain, and the third structural domain is a bZIP factor of human T-cell viro-1; the chemotactic factor ligand is CCL17 or CCL22, and the intermediate bridging structural domain is a flexible (GGGGS) 3 sequence; the bZIP factor of the human T cell viro-1 is HBZ (Hepatitis B Z). The fusion protein and the recombinant lentivirus both have the capabilities of promoting the differentiation of initial T cells to Treg cells and promoting the proliferation of the Treg cells, and have application potentials in the aspects of in-vitro Treg cell culture and amplification and the application of treating autoimmune diseases. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a GUO ZANZAN |4 aut | |
| 700 | 0 | |a XIE MIAOMIAO |4 aut | |
| 700 | 0 | |a GUO XIAOFANG |4 aut | |
| 700 | 0 | |a WANG HONGFEI |4 aut | |
| 700 | 0 | |a ZHAO LIJUN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 14. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88661521/publication/CN117050192A1?q=CN117050192 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 14 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 11 | ||